Results From IMPROVE Study Show Therapeutic Effect Of New Formulation Of Rebif(R) At 16 Weeks In Patients With Multiple Sclerosis September 24, 2008
If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.

add to del.icio.us
Print This Post































Leave a Reply